Treg cell therapy for ALS
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests a new type of cell therapy called regulatory T cells (Tregs) for people with neurodegenerative diseases like ALS. The goal is to see if these cells can slow down the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old
- You have been diagnosed with ALS (Lou Gehrig's disease)
- Your lung function is at least 70% of normal for your age
- You have not had any major surgery or been in another research trial in the last 2 weeks
- You do not have uncontrolled infections, heart disease, HIV, hepatitis B or C, or a history of cancer
- If you are able to have children, you agree to use effective birth control
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment made from stem cells (called XS228CN) injected into the spine. It is primarily a safety study, but doctors will also watch for any signs the treatment may slow ALS progression.
This trial tests a single injection of SNUG01 into the spinal fluid to see if it is safe and could help people with ALS. It is an early study to check for side effects and how well the treatment works.
This study tests a new gene therapy called VGN-R13 for people with ALS. It aims to see if the treatment is safe and tolerable, and if it can slow down the disease. You may be able to join if your ALS symptoms started recently and your lung function is still fairly good.
This trial offers a custom-made treatment for people with ALS caused by a TARDBP gene mutation. It uses a personalized medicine approach to target the specific genetic cause of the disease.
This trial tests a personalized medicine approach for people with ALS caused by changes in the TARDBP gene. The treatment uses a custom-made molecule to target the genetic cause and may help slow the disease.
This trial tests a new gene therapy called SNUG01 for adults with ALS. It aims to see if the treatment is safe and can slow the disease. You may be eligible if you are diagnosed early (within 2 years) and have good breathing function.
Hear when a new Amyotrophic Lateral Sclerosis (ALS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.